• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Patients with rheumatoid arthritis have impaired long-term outcomes after myocardial infarction: a nationwide case-control registry study
ConclusionRA is independently associated with poorer prognosis after MI. RA duration and corticosteroid usage and dosage were independent predictors of mortality after MI in RA. Special attention is needed for improvement of outcomes after MI in this vulnerable population.
Source: Rheumatology - March 1, 2021 Category: Rheumatology Source Type: research

Benefits of Methotrexate Use on Cardiovascular Disease Risk among Rheumatoid Arthritis Patients Initiating Biologic Disease-Modifying Antirheumatic Drugs.
CONCLUSION: Among RA patients receiving biologics, concomitant methotrexate use was associated with a 24% lower risk for CVD events. PMID: 33060309 [PubMed - as supplied by publisher]
Source: J Rheumatol - October 15, 2020 Category: Rheumatology Authors: Xie F, Chen L, Yun H, Levitan EB, Curtis JR Tags: J Rheumatol Source Type: research

The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis.
CONCLUSION: Abatacept and TNFi were associated with decreased risk of CVD compared to csDMARDs. Minimizing glucocorticoid use and optimizing MTX dose may improve CV outcomes in patients with RA. PMID: 32801134 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - August 18, 2020 Category: Rheumatology Tags: J Rheumatol Source Type: research

Cardiovascular comorbidities in rheumatoid arthritis.
Abstract Approximately 80% of patients with rheumatoid arthritis (RA) suffer from comorbidities including more than 50% from cardiovascular (CV) diseases. Inflammatory activity is the main factor connecting RA with atherosclerosis, coronary heart disease, stroke, thromboembolic events and heart failure. Altogether these affect RA patients twice as frequently as the general population and CV events are the major cause of death in RA. Besides inflammatory activity, which can be reduced or eliminated by optimal treatment and controlling the RA activity, traditional CV risk factors also contribute to the total CV ris...
Source: Zeitschrift fur Rheumatologie - January 17, 2019 Category: Rheumatology Authors: Krüger K, Nüßlein H Tags: Z Rheumatol Source Type: research

Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population ‐based retrospective cohort study
International Journal of Rheumatic Diseases, EarlyView.
Source: APLAR Journal of Rheumatology - January 25, 2018 Category: Rheumatology Source Type: research

Risk of Myocardial Infarction and Stroke in Patients With Granulomatosis With Polyangiitis (Wegener's): A Population ‐Based Study
ConclusionPatients with GPA have a significantly increased risk of MI and a non–statistically significant trend toward an increased risk of ischemic stroke. Monitoring for this complication and vigilance in modifying risk factors are particularly warranted in this patient population, especially early after the diagnosis of GPA.
Source: Arthritis and Rheumatism - September 28, 2016 Category: Rheumatology Authors: J. Antonio Avi ña‐Zubieta, Alice Mai, Neda Amiri, Natasha Dehghan, Ju Ann Tan, Eric C. Sayre, Hyon K. Choi Tags: Full Length Source Type: research

Risk of Myocardial Infarction and Stroke in Patients with Granulomatosis with Polyangiitis: A Population‐Based Study
Conclusion: GPA patients have a significantly increased risk of MI, with a non‐statistically significant trend towards increased risk of ischemic stroke. Monitoring for this complication and vigilance in modifying risk factors is particularly warranted in this patient population, especially early after diagnosis. This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatism - May 22, 2016 Category: Rheumatology Authors: J. Antonio Aviña‐Zubieta, Alice Mai, Neda Amiri, Natasha Dehghan, Ju Ann Tan, Eric C. Sayre, Hyon K. Choi Tags: Full Length Source Type: research

Tumor Necrosis Factor α Inhibitor Use and Decreased Risk for Incident Coronary Events in Rheumatoid Arthritis
ConclusionUse of TNFα inhibitors is associated with a decreased risk for CAD in RA; the risk decreases further with long‐term use. This should be considered when weighing the risks versus benefits of these medications.
Source: Arthritis Care and Research - February 24, 2014 Category: Rheumatology Authors: Androniki Bili, Xiaoqin Tang, Shruthi Pranesh, Rasa Bozaite, Stephanie J. Morris, Jana L. Antohe, H. Lester Kirchner, Mary Chester M. Wasko Tags: Rheumatoid Arthritis Source Type: research

Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)
Conclusions Among RA patients, there is a high prevalence of comorbidities and their risk factors. In this multinational sample, variability among countries was wide, not only in prevalence but also in compliance with recommendations for preventing and managing these comorbidities. Systematic measurement of vital signs and laboratory testing detects otherwise unrecognised comorbid conditions.
Source: Annals of the Rheumatic Diseases - December 4, 2013 Category: Rheumatology Authors: Dougados, M., Soubrier, M., Antunez, A., Balint, P., Balsa, A., Buch, M. H., Casado, G., Detert, J., El-zorkany, B., Emery, P., Hajjaj-Hassouni, N., Harigai, M., Luo, S.-F., Kurucz, R., Maciel, G., Mola, E. M., Montecucco, C. M., McInnes, I., Radner, H., Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Osteoporosis, Rheumatoid arthritis, Epidemiology, Calcium and bone Clinical and epidemiological research Source Type: research

TNF‐α inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis patients
Conclusion: Use of TNF‐α inhibitors is associated with a decreased risk for CAD in RA; the risk decreases further with longterm use. This should be considered when weighing the risks versus benefits of these medications. © 2013 American College of Rheumatology.
Source: Arthritis Care and Research - September 10, 2013 Category: Rheumatology Authors: Androniki Bili, Xiaoqin Tang, Shruthi Pranesh, Rasa Bozaite, Stephanie J. Morris DO, Jana L. Antohe, H. Lester Kirchner, Mary Chester M. Wasko Tags: Original Article Source Type: research